Teva Pharmaceutical Industries Ltd. (TEVA), Monday announced the launch of an authorized generic for Victoza injection with a quantity of 1.8 mg for type 2 diabetes patients in the U.S.
The injectable prescription medicine helps in lowering blood sugar levels in adults and children who are 10 years of age and older with type 2 diabetes mellitus, and reduces risk of cardiovascular disease, the company stated.
The biotechnology company added that Victoza had annual sales of $1.656 billion as of April 2024.
Currently, Teva's stock is falling 1.98 percent, to $16.63 on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Health News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.